Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. [electronic resource]
By: Contributor(s):- Badrising, Umesh A
- Benveniste, Olivier
- Lloyd, Thomas E
- Needham, Merrilee
- Chinoy, Hector
- Aoki, Masashi
- Machado, Pedro M
- Liang, Christina
- Reardon, Katrina A
- de Visser, Marianne
- Ascherman, Dana P
- Barohn, Richard J
- Dimachkie, Mazen M
- Miller, James A L
- Kissel, John T
- Oskarsson, Björn
- Joyce, Nanette C
- Van den Bergh, Peter
- Baets, Jonathan
- De Bleecker, Jan L
- Karam, Chafic
- David, William S
- Mirabella, Massimiliano
- Nations, Sharon P
- Jung, Hans H
- Pegoraro, Elena
- Maggi, Lorenzo
- Rodolico, Carmelo
- Filosto, Massimiliano
- Shaibani, Aziz I
- Sivakumar, Kumaraswamy
- Goyal, Namita A
- Mori-Yoshimura, Madoka
- Yamashita, Satoshi
- Suzuki, Naoki
- Katsuno, Masahisa
- Murata, Kenya
- Nodera, Hiroyuki
- Nishino, Ichizo
- Romano, Carla D
- Williams, Valerie S L
- Vissing, John
- Auberson, Lixin Zhang
- Wu, Min
- de Vera, Ana
- Papanicolaou, Dimitris A
- Amato, Anthony A
- 1474-4465
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
-
1
The Enduring Value of the Physical Examination.
by Zaman, Junaid A B -
2
Role of Rotors in the Ablative Therapy of Persistent Atrial Fibrillation.
by Schricker, Amir A -
3
Another method that shows organization in persistent AF? That's a RAAP.
by Baykaner, Tina -
4
The Value of Physical Examination: A New Conceptual Framework.
by Zaman, Junaid -
5
Mapping and Ablation of Rotational and Focal Drivers in Atrial Fibrillation.
by Zaman, Junaid -
6
The rotor revolution: conduction at the eye of the storm in atrial fibrillation.
by Zaman, Junaid A B -
7
Mechanistically based mapping of human cardiac fibrillation.
by Narayan, Sanjiv M -
8
Ablation of Atrial Fibrillation: How Can Less Be More?
by Zaman, Junaid A B -
9
Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease.
by Zaman, Junaid A B -
10
Ablating Atrial Fibrillation: Customizing Lesion Sets Guided by Rotor Mapping.
by Zaman, Junaid A B -
11
When Is Structure, Function? Revisiting an Old Concept in Atrial Fibrillation.
by Zaman, Junaid A B -
12
Particulate guanylyl cyclase and cholinergic control of cardiac excitability is site specific.
by Herring, Neil -
13
New Mechanism-based Approaches to Ablating Persistent AF: Will Drug Therapy Soon Be Obsolete?
by Zaman, Junaid A B -
14
Rotational Drivers in Atrial Fibrillation: Are Multiple Techniques Circling Similar Mechanisms?
by Zaman, Junaid A B -
15
Catheter ablation or surgery to eliminate longstanding persistent atrial fibrillation.
by Shah, Rajan L -
16
Rotor mapping and ablation to treat atrial fibrillation.
by Zaman, Junaid A B -
17
Mechanisms for the Termination of Atrial Fibrillation by Localized Ablation: Computational and Clinical Studies.
by Rappel, Wouter-Jan -
18
Mapping Ripples or Waves in Atrial Fibrillation?
by Zaman, Junaid A B -
19
Editorial commentary: What can lung transplantation teach us about the mechanisms of atrial arrhythmias?
by Baykaner, Tina -
20
Interpreting Activation Mapping of Atrial Fibrillation: A Hybrid Computational/Physiological Study.
by Sahli Costabal, Francisco
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.
APA
Hanna M. G., Badrising U. A., Benveniste O., Lloyd T. E., Needham M., Chinoy H., Aoki M., Machado P. M., Liang C., Reardon K. A., de Visser M., Ascherman D. P., Barohn R. J., Dimachkie M. M., Miller J. A. L., Kissel J. T., Oskarsson B., Joyce N. C., Van den Bergh P., Baets J., De Bleecker J. L., Karam C., David W. S., Mirabella M., Nations S. P., Jung H. H., Pegoraro E., Maggi L., Rodolico C., Filosto M., Shaibani A. I., Sivakumar K., Goyal N. A., Mori-Yoshimura M., Yamashita S., Suzuki N., Katsuno M., Murata K., Nodera H., Nishino I., Romano C. D., Williams V. S. L., Vissing J., Auberson L. Z., Wu M., de Vera A., Papanicolaou D. A. & Amato A. A. (20200609). Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. : The Lancet. Neurology.
Chicago
Hanna Michael G, Badrising Umesh A, Benveniste Olivier, Lloyd Thomas E, Needham Merrilee, Chinoy Hector, Aoki Masashi, Machado Pedro M, Liang Christina, Reardon Katrina A, de Visser Marianne, Ascherman Dana P, Barohn Richard J, Dimachkie Mazen M, Miller James A L, Kissel John T, Oskarsson Björn, Joyce Nanette C, Van den Bergh Peter, Baets Jonathan, De Bleecker Jan L, Karam Chafic, David William S, Mirabella Massimiliano, Nations Sharon P, Jung Hans H, Pegoraro Elena, Maggi Lorenzo, Rodolico Carmelo, Filosto Massimiliano, Shaibani Aziz I, Sivakumar Kumaraswamy, Goyal Namita A, Mori-Yoshimura Madoka, Yamashita Satoshi, Suzuki Naoki, Katsuno Masahisa, Murata Kenya, Nodera Hiroyuki, Nishino Ichizo, Romano Carla D, Williams Valerie S L, Vissing John, Auberson Lixin Zhang, Wu Min, de Vera Ana, Papanicolaou Dimitris A and Amato Anthony A. 20200609. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. : The Lancet. Neurology.
Harvard
Hanna M. G., Badrising U. A., Benveniste O., Lloyd T. E., Needham M., Chinoy H., Aoki M., Machado P. M., Liang C., Reardon K. A., de Visser M., Ascherman D. P., Barohn R. J., Dimachkie M. M., Miller J. A. L., Kissel J. T., Oskarsson B., Joyce N. C., Van den Bergh P., Baets J., De Bleecker J. L., Karam C., David W. S., Mirabella M., Nations S. P., Jung H. H., Pegoraro E., Maggi L., Rodolico C., Filosto M., Shaibani A. I., Sivakumar K., Goyal N. A., Mori-Yoshimura M., Yamashita S., Suzuki N., Katsuno M., Murata K., Nodera H., Nishino I., Romano C. D., Williams V. S. L., Vissing J., Auberson L. Z., Wu M., de Vera A., Papanicolaou D. A. and Amato A. A. (20200609). Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. : The Lancet. Neurology.
MLA
Hanna Michael G, Badrising Umesh A, Benveniste Olivier, Lloyd Thomas E, Needham Merrilee, Chinoy Hector, Aoki Masashi, Machado Pedro M, Liang Christina, Reardon Katrina A, de Visser Marianne, Ascherman Dana P, Barohn Richard J, Dimachkie Mazen M, Miller James A L, Kissel John T, Oskarsson Björn, Joyce Nanette C, Van den Bergh Peter, Baets Jonathan, De Bleecker Jan L, Karam Chafic, David William S, Mirabella Massimiliano, Nations Sharon P, Jung Hans H, Pegoraro Elena, Maggi Lorenzo, Rodolico Carmelo, Filosto Massimiliano, Shaibani Aziz I, Sivakumar Kumaraswamy, Goyal Namita A, Mori-Yoshimura Madoka, Yamashita Satoshi, Suzuki Naoki, Katsuno Masahisa, Murata Kenya, Nodera Hiroyuki, Nishino Ichizo, Romano Carla D, Williams Valerie S L, Vissing John, Auberson Lixin Zhang, Wu Min, de Vera Ana, Papanicolaou Dimitris A and Amato Anthony A. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. : The Lancet. Neurology. 20200609.